$Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis$
QR Code

QR Code

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis

With the introduction of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and radiation combined, the prognosis of Hodgkin lymphoma (HL) has significantly improved, with 5-year overall survival of around 90 %. While the lymphoma has become highly curable, the side effects of ABVD treatmen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Magdalena Witkowska, Mikołaj Malicki, Weronika Marcinkowska, Kacper Kościelny, Adrianna Kowalik, Damian Mikulski, Grzegorz Mirocha
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Leukemia Research Reports
Subjects:	Hodgkin lymphoma Nivolumab Anti-PD-1 agents Immunotherapy HL
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048925000214
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
by: D. D. Ivanova, et al.
Published: (2024-12-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study
by: Dmitry Shchelokov, et al.
Published: (2023-12-01)

Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2<sup>nd</sup> line treatment before autologous hematopoietic stem cell transplantation (preliminary results)
by: A. A. Mamedova, et al.
Published: (2022-07-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Tumor‐associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma
by: Maja Dam Andersen, et al.
Published: (2025-07-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Colitis grave inmunomediada por Nivolumab-Ipilimumab: a propósito de un caso
by: Maria Victoria Foglino, et al.
Published: (2025-07-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report
by: Yu. M. Bychkov, et al.
Published: (2019-07-01)

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report
by: Koji Yasuda, et al.
Published: (2017-08-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Observations on seasonal occurrence in lymphomas with proven or presumed infectious etiology
by: Ioannis Anagnostopoulos, et al.
Published: (2025-07-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report
by: Shunji Endo, et al.
Published: (2020-10-01)

Hodgkin lymphoma: current conception and unresolved questions
by: Gurtovoj V.A., et al.
Published: (2010-01-01)

Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab
by: Tsutomu Namikawa, et al.
Published: (2018-07-01)

PERIPHERAL BLOOD MONONUCLEAR DNA DAMAGE IDENTIFIED BY THE «СOMET» METHOD, AS A POSSIBLE INDICATOR OF SENSITIVITY OF MELANOMA TO IMMUNOTHERAPY WITH NIVOLUMAB
by: E. V. Tsyrlina, et al.
Published: (2021-05-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

New approaches for combined therapy of Hodgkin's lymphoma
by: P. V. Dacenko, et al.
Published: (2022-11-01)

A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus
by: Keita Hanada, et al.
Published: (2022-11-01)

Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
by: Illaa Smesseim, MD, et al.
Published: (2025-07-01)

A clinical case of immune-mediated pneumonitis after nivolumab in a patient with Burkitt lymphoma
by: K. I. Utesheva, et al.
Published: (2023-03-01)

Combined Use of Cabozantinib and Nivolumab in Clinical Practice
by: V. E. Askarov, et al.
Published: (2024-04-01)

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
by: Hiroshi Sawayama, et al.
Published: (2022-12-01)

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer
by: Chen Jun, et al.
Published: (2023-05-01)

Nivolumab in real-life clinical practice
by: M. A. Lyadova, et al.
Published: (2019-12-01)

Criptococosis sistémica en un paciente con linfoma no Hodgkin
by: Alvaro Sandoval Salavarrieta, et al.
Published: (2004-10-01)

ORBITAL NON-HODGKIN’S LYMPHOMAS
by: S. V. Saakyan, et al.
Published: (2015-04-01)

Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma
by: N. V. Ilyin, et al.
Published: (2022-11-01)

Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma
by: Pukiat, Sulada, et al.
Published: (2012)

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma
by: Fernández, Karen S., et al.
Published: (2012)